Literature DB >> 33093057

Intraoral midline mandibulotomy to improve access for transoral robotic surgery (TORS) base of tongue resection in a retrognathic and microstomic patient.

Daniel Bestourous1, Margaret Michel2, Christopher Badger2, Punam Thakkar2, Arjun S Joshi2.   

Abstract

A 74-year-old man was referred to a tertiary academic otolaryngology clinic for evaluation of a left-sided neck mass with unknown primary. Nuclear imaging modalities revealed a primary cancer located at the left tongue base. Further investigation revealed the tumour to be a p16 positive squamous cell cancer with metastatic spread to cervical lymph nodes of multiple levels. The patient was found on initial investigation to have microstomia and a retrognathic mandible, which are typically considered unsuitable for robotic surgery due to difficulties obtaining adequate exposure.The patient underwent bilateral neck dissection, followed by transoral robotic-assisted left base of tongue resection. A midline intraoral mandibulotomy was performed to improve robotic access. Following tumour resection, the mandible was repaired using open reduction with internal plate fixation. Postoperative occlusion was maintained, and the patient recovered well from mandibulotomy with none of the morbidity or cosmetic defects associated with a traditional lip-split approach. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ear; head and neck cancer; head and neck surgery; nose and throat/otolaryngology; otolaryngology / ENT; surgical oncology

Mesh:

Year:  2020        PMID: 33093057      PMCID: PMC7583074          DOI: 10.1136/bcr-2020-236010

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

Review 1.  Management of mandibular invasion: when is a marginal mandibulectomy appropriate?

Authors:  Eric M Genden; Alessandra Rinaldo; Adam Jacobson; Ashok R Shaha; Carlos Suárez; John Lowry; Andrew C Urquhart; Jochen A Werner; Patrick J Gullane; Alfio Ferlito
Journal:  Oral Oncol       Date:  2005-03-16       Impact factor: 5.337

2.  Mandibular osteotomy for expanded transoral robotic surgery: a novel technique.

Authors:  Alfred Marc C Iloreta; Katie Anderson; Brett A Miles
Journal:  Laryngoscope       Date:  2014-02-10       Impact factor: 3.325

3.  Understanding contraindications for transoral robotic surgery (TORS) for oropharyngeal cancer.

Authors:  Gregory S Weinstein; Bert W O'Malley; Alessandra Rinaldo; Carl E Silver; Jochen A Werner; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-20       Impact factor: 2.503

4.  Use of a midline mandibular osteotomy to improve surgical access for transoral robotic resection of the base of tongue in a patient with trismus.

Authors:  Gerald Tay; Jay Ferrell; Peter Andersen
Journal:  Head Neck       Date:  2017-06-29       Impact factor: 3.147

5.  Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer.

Authors:  Nader Sadeghi; Sarah Khalife; Marco A Mascarella; Agnihotram V Ramanakumar; Keith Richardson; Arjun S Joshi; Nathaniel Bouganim; Reza Taheri; Andrew Fuson; Robert Siegel
Journal:  Head Neck       Date:  2019-11-27       Impact factor: 3.147

6.  Transoral robotic surgery (TORS) for base of tongue neoplasms.

Authors:  Bert W O'Malley; Gregory S Weinstein; Wendy Snyder; Neil G Hockstein
Journal:  Laryngoscope       Date:  2006-08       Impact factor: 3.325

7.  Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins.

Authors:  Gregory S Weinstein; Bert W O'Malley; J Scott Magnuson; William R Carroll; Kerry D Olsen; Lixia Daio; Eric J Moore; F Christopher Holsinger
Journal:  Laryngoscope       Date:  2012-07-02       Impact factor: 3.325

Review 8.  Transoral robotic surgery for oropharyngeal cancer: patient selection and special considerations.

Authors:  R Michael Baskin; Brian J Boyce; Robert Amdur; William M Mendenhall; Kathryn Hitchcock; Natalie Silver; Peter T Dziegielewski
Journal:  Cancer Manag Res       Date:  2018-04-20       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.